Core Insights - The core message of the article emphasizes the investment philosophy of Terry Smith and Fundsmith, focusing on principles such as buying good companies, not overpaying, and maintaining a long-term perspective without frequent trading [1][4][7]. Investment Philosophy - Fundsmith's investment strategy is based on three key principles: 1. Buy good companies, defined by strong financial metrics such as high return on capital employed (ROCE) and gross margin [5][6]. 2. Don't overpay, with a focus on free cash flow yield as a measure of valuation [6][7]. 3. Do nothing, meaning that the best returns come from holding quality companies over time rather than frequent trading [7][8]. Market Trends and Insights - The discussion highlighted the impact of GLP-1 weight loss drugs, with the global market expected to grow from approximately $31.6 billion to between $100 billion and $350 billion in the coming years [8][9]. - The article also addressed the implications of potential tariff increases under a returning Trump administration, emphasizing that investment decisions should focus on the fundamental business operations rather than unpredictable political changes [10][11]. Active vs. Passive Management - Terry Smith argued that active management has a future, as it allows for selective investment in quality companies, contrasting with passive strategies that may lead to overvaluation of large-cap stocks [3][4]. - The article discussed the importance of understanding the underlying business quality and resilience in the face of market changes, rather than merely following market trends [10][11]. Controversial Holdings - Fundsmith's controversial holdings include Philip Morris, Novo Nordisk, and Unilever, each facing different market debates regarding ESG concerns, valuation, and management effectiveness [2][20][21]. - The article noted that Philip Morris has shifted significantly towards reduced-risk products, with a substantial portion of its revenue now coming from non-combustible products [20]. - Novo Nordisk's valuation concerns were addressed, with a focus on its strong financial metrics compared to competitors [21]. Management Incentives - The article highlighted the importance of management incentive structures, with Fundsmith often opposing poorly designed compensation plans that do not align with long-term shareholder value [15][16]. - Effective incentive mechanisms were illustrated through examples of companies that successfully align management goals with shareholder interests [16][19]. Dividend Strategy - Fundsmith's stance against investing solely for dividends was emphasized, advocating for a focus on companies that can reinvest profits effectively for long-term growth [17][19]. - The article provided examples of companies that have successfully increased dividends over time, reinforcing the idea that strong growth potential is more critical than immediate dividend yields [19].

Core Viewpoint - Boston Scientific (BSX) is experiencing growth driven by product launches, strategic acquisitions, and international expansion, with a Zacks Rank of 2 (Buy) indicating positive market sentiment [1]. Group 1: Growth Drivers - The company is successfully expanding its operations internationally, particularly in Europe, the Middle East, and Africa (EMEA), where sales grew 11.6% year over year on an operational basis in the fourth quarter [2]. - New product launches, such as the next-generation accurate Prime Valve and LUX-Dx II, along with strong uptake of FARAPULSE, are contributing to growth in the EMEA region [2]. - The Endoscopy business within MedSurg is seeing strong growth in endoluminal surgery and single-use imaging franchises, supported by positive reimbursement wins for the ESG weight loss procedure [3]. Group 2: Strategic Acquisitions - Recent acquisitions, including Cortex for advanced AF mapping and Silk Road for vascular medicine, are expected to enhance the product portfolio and boost long-term revenue [4]. - The acquisition of Axonics in the fourth quarter of 2024 is also part of the company's strategy to expand its offerings [4]. Group 3: Stock Performance - Over the past three months, BSX shares have increased by 14.1%, outperforming the industry, which saw a decline of 5.7% [5]. - The company's international market expansion and new product launches are anticipated to sustain this upward trend in stock performance [5]. Group 4: Challenges - The company faces challenges from difficult macroeconomic conditions, including geopolitical pressures and disruptions in global supply chains, which may impact operating expenses [6]. - In the fourth quarter of 2024, BSX experienced a 27.9% increase in the cost of products sold, leading to a contraction in gross margin by 138 basis points [6]. - Currency fluctuations pose a risk, with 40% of sales coming from international markets, and a projected 100-basis point headwind from foreign exchange on revenues for 2025 [7]. Group 5: Competitive Landscape - The medical devices market is highly competitive, with Boston Scientific facing competition from major players like Johnson & Johnson, Abbott, Medtronic, Stryker, Smith & Nephew, and Edwards Lifesciences [8].

Financial Data and Key Metrics Changes - Stryker's Orthopedic business grew by approximately 8.5% in the first half of 2024, with a 9% growth when adjusted for selling days [2][3] - The company reported a mid-single-digit growth expectation for hip and knee procedures, up from low-single-digit pre-pandemic levels [6][8] - Pricing in orthopedics improved to less negative, with a first half decline of only 0.3%, compared to historical declines of 2% to 3% [11][12][15] Business Line Data and Key Metrics Changes - The Trauma and Extremities business outperformed expectations, with strong performance in core trauma and upper extremities [3][10] - Mako installations reached record levels in Q2, contributing to strong demand for orthopedic products [16][18] - The Pangea system in trauma is expected to provide additional growth, although its impact is still in early stages [55][58] Market Data and Key Metrics Changes - The demographic shift with more individuals over 65 years old is driving demand for hip and knee procedures, with 12,000 Americans turning 65 daily [6][7] - The capital environment remains healthy, with hospitals willing to invest in technology to improve patient care and efficiency [19] Company Strategy and Development Direction - Stryker is focused on a share-taking strategy across its orthopedic businesses, aiming to outperform market growth rates [66] - The company is committed to innovation and investment in its Mako platform, with plans to expand applications into shoulder and spine [23][25] - The acquisition of Vertos is part of Stryker's strategy to enhance its interventional spine offerings, targeting earlier treatment options for patients [74][75] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth, with expectations for a solid performance in the second half of 2024 and into 2025 [4][66] - The company is optimistic about the impact of new product introductions, including Mako for spine and shoulder, on future growth [66] Other Important Information - Stryker's customer solutions organization aims to enhance collaboration between its MedSurg and orthopedic divisions, driving growth in ambulatory surgery centers [69][70] - The company is actively pursuing tuck-in acquisitions to bolster its portfolio and maintain growth momentum [75] Q&A Session Summary Question: What drove the growth in Orthopedics? - Strong demand for products, particularly Mako technology, and new product introductions contributed to growth [3] Question: How are procedure volumes expected to trend? - Volumes are expected to continue increasing, driven by demographic changes and improved patient willingness for outpatient procedures [6][7] Question: What is the outlook for pricing in orthopedics? - Pricing has improved significantly, with a focus on building competency in pricing strategies [12][15] Question: How is Stryker addressing competition and market share? - The company is focused on a share-taking strategy and has seen success in its orthopedic businesses [21][60] Question: What is the expected impact of Mako on future growth? - Mako is expected to drive significant growth, with plans for new applications in spine and shoulder [25][36] Question: How does Stryker coordinate between MedSurg and orthopedics? - The company emphasizes collaboration through its customer solutions organization to align strategies and drive growth [69][70]

Stryker Corporation. (NYSE:SYK) 5th Annual Evercore ISI HealthCONx Conference 2022 December 1, 2022 8:50 AM ET Company Participants Kevin Lobo - Chief Executive Officer Jason Beach - Vice President, Investor Relations Lara Mordoh - Senior Director, Investor Relations Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar Great. Thanks everyone for joining us this morning. A pleasure to have with us the team from Stryker. We have CEO Kevin Lobo with us this morning. And from investor relations, ...